SternAegis seeks to invest in the technology, telecom, media, internet, and emerging growth sectors.
Business Model:
Revenue: $0
Employees: 0-0
Address: 810 7th Ave
City: New York
State: NY
Zip: 10019
Country: US
SternAegis Ventures is a corporate venture arm of Aegis Capital that began operation on January 1, 2012, with its headquarters in New York City. It seeks to invest in the technology, telecom, media, internet, and emerging growth sectors. It offers large firm execution capability with a small firm service approach. It bridges the gap between emerging growth companies and the capital markets by providing investment banking services and principal investment. It is well-equipped to assist in the capital formation of companies seeking to progress from private financing to accessing capital from the public markets.
Contact Phone:
+16465022401
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
12/2012 | Organovo Holdings | Post-IPO Equity | 25M |
4/2020 | Outstanding Foods | Venture Round | 5M |
5/2013 | Armada Water Assets | Venture Round | 10M |
3/2022 | Amplifica | Series A | 11.8M |
3/2021 | ZoomCar | Series A | 0 |
1/2013 | GlobeImmune | Venture Round | 7.5M |
5/2013 | Deem | Venture Round | 12.5M |
10/2016 | Helocyte | Venture Round | 4M |
1/2021 | Outstanding Foods | Series A | 0 |
1/2018 | Orchestra BioMed | Venture Round | 22.8M |
9/2021 | Aerami Therapeutics | Venture Round | 22.3M |
1/2022 | Orchestra BioMed | Series D | 0 |
8/2021 | Viscient Biosciences | Convertible Note | 0 |
5/2016 | Kintara Therapeutics | Post-IPO Equity | 9.5M |
8/2021 | DermaSensor | Series B | 0 |
5/2021 | Hydrobuilder.com | Venture Round | 60M |
9/2021 | Aerami Therapeutics | Venture Round | 22.3M |
11/2017 | BackBeat Medical | Venture Round | 4M |
5/2013 | MATINAS BIOPHARMA | Venture Round | 33M |
11/2021 | Outstanding Foods | Venture Round | 0 |
10/2015 | Aerami Therapeutics | Venture Round | 20M |
4/2013 | DarioHealth | Venture Round | 10M |
8/2022 | Clover | Venture Round | 6M |
12/2016 | Motus GI | Venture Round | 0 |
6/2020 | DermaSensor | Series A | 11.5M |
9/2022 | Aerami Therapeutics | Series B | 5.4M |
9/2017 | Adgero Biopharmaceuticals | Venture Round | 3.4M |
3/2019 | Orchestra BioMed | Series B | 34M |
12/2021 | Psudo | Seed Round | 3M |
6/2017 | Calibertherapeutics | Venture Round | 12M |
10/2019 | DarioHealth | Post-IPO Equity | 21.3M |
11/2017 | Aerami Therapeutics | Venture Round | 13.9M |
3/2014 | Corbus Pharmaceuticals | Venture Round | 20M |
7/2021 | ZoomCar | Series E | 0 |
10/2011 | InVivo Therapeutics | Post-IPO Equity | 30M |
11/2007 | PROLOR Biotech | Venture Round | 30M |
9/2016 | Adgero Biopharmaceuticals | Venture Round | 9.7M |
3/2020 | Aerami Therapeutics | Venture Round | 12.4M |
8/2018 | Hydrofarm | Venture Round | 29.4M |
7/2020 | DarioHealth | Post-IPO Equity | 28.6M |
1/2022 | Orchestra BioMed | Series D | 0 |
12/2021 | Psudo | Seed Round | 0 |
11/2021 | Outstanding Foods | Venture Round | 0 |
9/2021 | Aerami Therapeutics | Funding Round | 0 |
8/2021 | DermaSensor | Series B | 0 |
8/2021 | Viscient Biosciences | Convertible Note | 0 |
7/2021 | ZoomCar | Series E | 0 |
5/2021 | Hydrobuilder.com | Venture Round | 0 |
3/2021 | ZoomCar | Series A | 0 |
1/2021 | Outstanding Foods | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|